{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:04:03Z","timestamp":1777896243578,"version":"3.51.4"},"reference-count":38,"publisher":"Journal of the ASEAN Federation of Endocrine Societies (JAFES)","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J ASEAN Fed Endocr Soc"],"abstract":"<jats:p>Background. The \u201cpillar approach\u201d was recently proposed to holistically address diabetic kidney disease (DKD). Theptarin Diabetes Staging (TDS) is a staging system for type 2 diabetes (T2D) designed to prevent or delay the progression to advanced stages.\nObjective. To evaluate the rate of guideline-directed medical therapies (GDMT) among individuals with DKD from 2021 to 2025 according to the TDS system.\nMethodology. A retrospective review of medical records of T2D patients with TDS stage 4Ka (moderately increased persistent albuminuria), Stage 4Kb (severely increased persistent albuminuria), and stage 5Ka (eGFR &lt;45 mL\/min\/1.73 m\u00b2) was conducted. The rates of RASi, SGLT2i, GLP-1 RA, and finerenone use, along with achievement of metabolic targets, were evaluated prospectively from 2021 to 2025.\nResults. A total of 206 medical records were reviewed (mean age 64.1 \u00b1 10.3 years, A1C 7.3 \u00b1 1.2%, mean eGFR 71.6 \u00b1 24.5 mL\/min\/1.73 m\u00b2). In 2021, the use of RASi was 78.2%, 51.5% for SGLT2i and 13.6% for GLP-1 RA among all patients. Four years later, rates of GDMT improved as follows: RASi 79.7%, SGLT2i 59.3%, GLP-1 RA 19.8% and finerenone 2.8%. However, only 1.1% of all patients in 2025 received all 4 GDMT items. More stable or improved TDS were observed in patients who received GDMT \u22653 classes across all 4 medication classes, compared with those who received GDMT &lt;3 classes (96.2% vs. 78.8%, P-value = 0.036).\nConclusion. The real-world implementation of GDMT among DKD patients remains inadequate, and more efforts are required to improve GDMT adoption. Regular reviews and feedback are warranted to improve attainment of treatment targets and better clinical outcomes.<\/jats:p>","DOI":"10.15605\/jafes.041.01.6239","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:18:04Z","timestamp":1777623484000},"source":"Crossref","is-referenced-by-count":0,"title":["Guideline-Directed Medical Therapies for Diabetic Kidney Disease Among Thai People With Type 2 Diabetes"],"prefix":"10.15605","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6048-3716","authenticated-orcid":false,"given":"Peachaphol","family":"Chongvoranond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-6693","authenticated-orcid":false,"given":"Waralee","family":"Chatchomchuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekgaluck","family":"Wanothayaroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriwan","family":"Butadej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5032-8296","authenticated-orcid":false,"given":"Soontaree","family":"Nakasatien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6441-9826","authenticated-orcid":false,"given":"Thep","family":"Himathongkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-4041","authenticated-orcid":false,"given":"Yotsapon","family":"Thewjitcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6244","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"85202","doi-asserted-by":"crossref","unstructured":"Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-84. https:\/\/pubmed.ncbi.nlm.nih.gov\/8521790 https:\/\/doi.org\/10.1210\/edrv-16-4-460","DOI":"10.1210\/edrv-16-4-460"},{"key":"85203","doi-asserted-by":"crossref","unstructured":"Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (\"incidentaloma\"). Ann Intern Med. 2003;138(5):424-9. https:\/\/pubmed.ncbi.nlm.nih.gov\/12614096 https:\/\/doi.org\/10.7326\/0003-4819-138-5-200303040-00013","DOI":"10.7326\/0003-4819-138-5-200303040-00013"},{"key":"85204","doi-asserted-by":"crossref","unstructured":"Lam KY, Lo CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol (Oxf). 2001;54(5):633-9. https:\/\/pubmed.ncbi.nlm.nih.gov\/11380494 https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01266.x","DOI":"10.1046\/j.1365-2265.2001.01266.x"},{"key":"85205","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1-G34. https:\/\/pubmed.ncbi.nlm.nih.gov\/27390021 https:\/\/doi.org\/10.1530\/EJE-16-0467","DOI":"10.1530\/EJE-16-0467"},{"key":"85206","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2023;189(1):G1-G42. https:\/\/doi.org\/10.1093\/ejendo\/lvad066","DOI":"10.1093\/ejendo\/lvad066"},{"key":"85207","doi-asserted-by":"crossref","unstructured":"Zeiger MA, Thompson GB, Duh QY, et al. American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. Endocr Pract. 2009;15(5):450-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/19632968 https:\/\/doi.org\/10.4158\/EP.15.5.450","DOI":"10.4158\/EP.15.5.450"},{"key":"85208","doi-asserted-by":"crossref","unstructured":"Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul). 2017;32(2):200-18. https:\/\/pubmed.ncbi.nlm.nih.gov\/28685511 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5503865 https:\/\/doi.org\/10.3803\/EnM.2017.32.2.200","DOI":"10.3803\/EnM.2017.32.2.200"},{"key":"85209","doi-asserted-by":"crossref","unstructured":"Pelsma ICM, Fassnacht M, Tsagarakis S, et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: Systematic review and meta-analysis. Eur J Endocrinol. 2023;189(4):S88-S101. https:\/\/pubmed.ncbi.nlm.nih.gov\/37801655 https:\/\/doi.org\/10.1093\/ejendo\/lvad134","DOI":"10.1093\/ejendo\/lvad134"},{"key":"85210","doi-asserted-by":"crossref","unstructured":"Adamska A, Ulychnyi V, Siewko K, et al. Cardiovascular risk factors in mild adrenal autonomous cortisol secretion in a Caucasian population. Endocr Connect. 2022;11(9):e220074. https:\/\/pubmed.ncbi.nlm.nih.gov\/35900803 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9422244 https:\/\/doi.org\/10.1530\/EC-22-0074","DOI":"10.1530\/endoabs.81.EP18"},{"key":"85211","doi-asserted-by":"crossref","unstructured":"Araujo-Castro M, Reincke M, Lamas C. Epidemiology and management of hypertension and diabetes mellitus in patients with mild autonomous cortisol secretion: A review. Biomedicines. 2023;11(12):3115. https:\/\/pubmed.ncbi.nlm.nih.gov\/38137336 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10740610 https:\/\/doi.org\/10.3390\/biomedicines11123115","DOI":"10.3390\/biomedicines11123115"},{"key":"85212","doi-asserted-by":"crossref","unstructured":"Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery. 2012;152(6):991-7. https:\/\/pubmed.ncbi.nlm.nih.gov\/23158173 https:\/\/doi.org\/10.1016\/j.surg.2012.08.054","DOI":"10.1016\/j.surg.2012.08.054"},{"key":"85213","doi-asserted-by":"crossref","unstructured":"Koh JM, Song K, Kwak MK, et al. Adrenalectomy improves body weight, glucose, and blood pressure control in patients with mild autonomous cortisol secretion: Results of a randomized controlled trial by the Co-work of Adrenal Research (COAR) study. Ann Surg. 2024;279(6):945-52. https:\/\/pubmed.ncbi.nlm.nih.gov\/38126763 https:\/\/doi.org\/10.1097\/SLA.0000000000006183","DOI":"10.1097\/SLA.0000000000006183"},{"key":"85214","doi-asserted-by":"crossref","unstructured":"Terzolo M, Pia A, Al\u00ec A, et al. Adrenal incidentaloma: A new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998-1003. https:\/\/pubmed.ncbi.nlm.nih.gov\/11889151 https:\/\/doi.org\/10.1210\/jcem.87.3.8277","DOI":"10.1210\/jc.87.3.998"},{"key":"85215","doi-asserted-by":"crossref","unstructured":"Favero V, Cremaschi A, Parazzoli C, et al. Pathophysiology of mild hypercortisolism: From the bench to the bedside. Int J Mol Sci. 2022;23(2):673. https:\/\/pubmed.ncbi.nlm.nih.gov\/35054858 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8775422 https:\/\/doi.org\/10.3390\/ijms23020673","DOI":"10.3390\/ijms23020673"},{"key":"85216","doi-asserted-by":"crossref","unstructured":"Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-70. https:\/\/pubmed.ncbi.nlm.nih.gov\/21471169 https:\/\/doi.org\/10.1530\/EJE-10-1147","DOI":"10.1530\/EJE-10-1147"},{"key":"85217","doi-asserted-by":"crossref","unstructured":"Androulakis II, Kaltsas GA, Kollias GE, et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab. 2014;99(8):2754-62. https:\/\/doi.org\/10.1210\/jc.2013-4064","DOI":"10.1210\/jc.2013-4064"},{"key":"85218","doi-asserted-by":"crossref","unstructured":"Park SH, Kim MJ, Kim JH, et al. Differentiation of adrenal adenoma and nonadenoma in unenhanced CT: New optimal threshold value and the usefulness of size criteria for differentiation. Korean J Radiol. 2007;8(4):328-35. https:\/\/pubmed.ncbi.nlm.nih.gov\/17673844 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2627166 https:\/\/doi.org\/10.3348\/kjr.2007.8.4.328","DOI":"10.3348\/kjr.2007.8.4.328"},{"key":"85219","doi-asserted-by":"crossref","unstructured":"Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas\/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871-7. https:\/\/pubmed.ncbi.nlm.nih.gov\/15572420 https:\/\/doi.org\/10.1210\/jc.2004-1627","DOI":"10.1210\/jc.2004-1627"},{"key":"85220","doi-asserted-by":"crossref","unstructured":"Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab. 2021;106(11):3331-53. https:\/\/pubmed.ncbi.nlm.nih.gov\/34260734 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8530736 https:\/\/doi.org\/10.1210\/clinem\/dgab512","DOI":"10.1210\/clinem\/dgab512"},{"key":"85221","doi-asserted-by":"crossref","unstructured":"Stavropoulos K, Imprialos KP, Katsiki N, et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone? J Clin Hypertens (Greenwich). 2018;20(5):942-8. https:\/\/pubmed.ncbi.nlm.nih.gov\/29722113 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8031295 https:\/\/doi.org\/10.1111\/jch.13291","DOI":"10.1111\/jch.13291"},{"key":"85222","doi-asserted-by":"crossref","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. https:\/\/pubmed.ncbi.nlm.nih.gov\/26934393 https:\/\/doi.org\/10.1210\/jc.2015-4061","DOI":"10.1210\/jc.2015-4061"},{"key":"85223","doi-asserted-by":"crossref","unstructured":"Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: A systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107-16. https:\/\/pubmed.ncbi.nlm.nih.gov\/31234202 https:\/\/doi.org\/10.7326\/M18-3630","DOI":"10.7326\/M18-3630"},{"key":"85224","doi-asserted-by":"crossref","unstructured":"Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. J Clin Endocrinol Metab. 2014;99(3):827-34. https:\/\/pubmed.ncbi.nlm.nih.gov\/24423350 https:\/\/doi.org\/10.1210\/jc.2013-3527","DOI":"10.1210\/jc.2013-3527"},{"key":"85225","doi-asserted-by":"crossref","unstructured":"Pasternak JD, Seib CD, Seiser N, et al. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg. 2015;150(10):974-8. https:\/\/pubmed.ncbi.nlm.nih.gov\/26200882 https:\/\/doi.org\/10.1001\/jamasurg.2015.1683","DOI":"10.1001\/jamasurg.2015.1683"},{"key":"85226","doi-asserted-by":"crossref","unstructured":"Vassiliadi DA, Ntali G, Stratigou T, et al. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine. 2011;40(3):437-44. https:\/\/pubmed.ncbi.nlm.nih.gov\/21598069 https:\/\/doi.org\/10.1007\/s12020-011-9490-1","DOI":"10.1007\/s12020-011-9490-1"},{"key":"85227","doi-asserted-by":"crossref","unstructured":"Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: A 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405. https:\/\/pubmed.ncbi.nlm.nih.gov\/24795253 https:\/\/doi.org\/10.1016\/S2213-8587(13)70211-0","DOI":"10.1016\/S2213-8587(13)70211-0"},{"key":"85228","doi-asserted-by":"crossref","unstructured":"Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736-45. https:\/\/pubmed.ncbi.nlm.nih.gov\/20375210 https:\/\/doi.org\/10.1210\/jc.2009-2387","DOI":"10.1210\/jc.2009-2387"},{"key":"85229","doi-asserted-by":"crossref","unstructured":"Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-85. https:\/\/pubmed.ncbi.nlm.nih.gov\/14514341 https:\/\/doi.org\/10.1530\/eje.0.1490273","DOI":"10.1530\/eje.0.1490273"},{"key":"85230","doi-asserted-by":"crossref","unstructured":"Giovanelli L, Aresta C, Favero V, et al. Hidden hypercortisolism: A too frequently neglected clinical condition. J Endocrinol Invest. 2021;44(8):1581-96. https:\/\/pubmed.ncbi.nlm.nih.gov\/33394454 https:\/\/doi.org\/10.1007\/s40618-020-01484-2","DOI":"10.1007\/s40618-020-01484-2"},{"key":"85231","doi-asserted-by":"crossref","unstructured":"Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: Consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519-48. https:\/\/pubmed.ncbi.nlm.nih.gov\/29905835 https:\/\/doi.org\/10.1210\/er.2018-00097","DOI":"10.1210\/er.2018-00097"},{"key":"85232","doi-asserted-by":"crossref","unstructured":"Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res. 2011;26(8):1816-21. https:\/\/pubmed.ncbi.nlm.nih.gov\/21472775 https:\/\/doi.org\/10.1002\/jbmr.398","DOI":"10.1002\/jbmr.398"},{"key":"85233","doi-asserted-by":"crossref","unstructured":"Hadjidakis D, Tsagarakis S, Roboti C, et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol (Oxf). 2003;58(1):72-7. https:\/\/pubmed.ncbi.nlm.nih.gov\/12519415 https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01676.x","DOI":"10.1046\/j.1365-2265.2003.01676.x"},{"key":"85234","doi-asserted-by":"crossref","unstructured":"Pal R, Banerjee M, Prasad TN, et al. Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion\/subclinical hypercortisolism: A systematic review, meta-analysis and meta-regression. J Bone Miner Res. 2024;39(7):885-97. https:\/\/pubmed.ncbi.nlm.nih.gov\/38703381 https:\/\/doi.org\/10.1093\/jbmr\/zjae067","DOI":"10.1093\/jbmr\/zjae067"},{"key":"85235","doi-asserted-by":"crossref","unstructured":"Tabarin A, Espiard S, Deutschbein T, et al. Surgery for the treatment of arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion (CHIRACIC): A multicentre, open-label, superiority randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):580-90. https:\/\/pubmed.ncbi.nlm.nih.gov\/40373786 https:\/\/doi.org\/10.1016\/S2213-8587(25)00062-2","DOI":"10.1016\/S2213-8587(25)00062-2"},{"key":"85236","doi-asserted-by":"crossref","unstructured":"Ren X, Nan M, Zhang X. Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: A meta-analysis. Front Endocrinol (Lausanne). 2024;15:1399311. https:\/\/pubmed.ncbi.nlm.nih.gov\/39086899 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11288901 https:\/\/doi.org\/10.3389\/fendo.2024.1399311","DOI":"10.3389\/fendo.2024.1399311"},{"key":"85237","doi-asserted-by":"crossref","unstructured":"Cho YY, Suh S, Joung JY, et al. Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med. 2013;28(5):557-64. https:\/\/pubmed.ncbi.nlm.nih.gov\/24009451 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3759761 https:\/\/doi.org\/10.3904\/kjim.2013.28.5.557","DOI":"10.3904\/kjim.2013.28.5.557"},{"key":"85238","doi-asserted-by":"crossref","unstructured":"Liu M, Zhao W, Zhang W, et al. Comparable cognitive impairment was detected in MACS and CS and alleviated after remission of hypercortisolism in MACS. Front Endocrinol (Lausanne). 2024;15:1373101. https:\/\/pubmed.ncbi.nlm.nih.gov\/39145316 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11322108 https:\/\/doi.org\/10.3389\/fendo.2024.1373101","DOI":"10.3389\/fendo.2024.1373101"},{"key":"85239","doi-asserted-by":"crossref","unstructured":"Luk Y, Tsang VHM, Lo C, Lee R, Cheung YT, Wong KK, et al. Prevalence of mild autonomous cortisol secretion in adrenal incidentalomas and the significance of subcentimeter adrenal nodules: A single-center cohort study. Endocr Pract. 2025;31(12):1576-84. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.018","DOI":"10.1016\/j.eprac.2025.07.018"}],"container-title":["Journal of the ASEAN Federation of Endocrine Societies"],"original-title":[],"link":[{"URL":"https:\/\/asean-endocrinejournal.org\/index.php\/JAFES\/article\/download\/6239\/5337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/asean-endocrinejournal.org\/index.php\/JAFES\/article\/download\/6239\/5337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:18:16Z","timestamp":1777623496000},"score":1,"resource":{"primary":{"URL":"https:\/\/asean-endocrinejournal.org\/index.php\/JAFES\/article\/view\/6239"}},"subtitle":["A Real-World Data Based on Theptarin Diabetes Staging"],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":38,"URL":"https:\/\/doi.org\/10.15605\/jafes.041.01.6239","relation":{},"ISSN":["2308-118X","0857-1074"],"issn-type":[{"value":"2308-118X","type":"electronic"},{"value":"0857-1074","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}